NOTUM inhibition increases endocortical bone formation and bone strength

Abstract

The disability, mortality and costs caused by non-vertebral osteoporotic fractures are enormous. Existing osteoporosis therapies are highly effective at reducing vertebral but not non-vertebral fractures. Cortical bone is a major determinant of non-vertebral bone strength. To identify novel osteoporosis drug targets, we phenotyped cortical bone of 3 366 viable mouse strains with global knockouts of druggable genes. Cortical bone thickness was substantially elevated in Notum ^−/− mice. NOTUM is a secreted WNT lipase and we observed high NOTUM expression in cortical bone and osteoblasts but not osteoclasts. Three orally active small molecules and a neutralizing antibody inhibiting NOTUM lipase activity were developed. They increased cortical bone thickness and strength at multiple skeletal sites in both gonadal intact and ovariectomized rodents by stimulating endocortical bone formation. Thus, inhibition of NOTUM activity is a potential novel anabolic therapy for strengthening cortical bone and preventing non-vertebral fractures.

Bone Development: NOTUM inhibition stimulates bone formation

NOTUM is an enzyme that inactivates WNT proteins (which play a key role in early tissue development), and inhibiting NOTUM has been found to increase the formation of endocortical bone (within the cortex, the hard exterior of bone) and enhance bone strength. Existing therapies for osteoporosis (condition causing bone to become weak and brittle) are effective in reducing vertebral, but not non-vertebral, fractures. A team headed by Robert Brommage at Lexicon Pharmaceuticals, Texas aimed to identify novel osteoporosis drug targets in mice. Following inhibition of NOTUM activity, the authors observed increased cortical bone thickness and strength at multiple skeletal sites through stimulation of endocortical bone formation. The team concluded that inhibiting NOTUM activity has good potential as a new therapeutic strategy and could be beneficial in preventing non-vertebral osteoporotic fractures.

References

[1] Harvey N, Dennison E, Cooper C. Osteoporosis: impact on health and economics. Nat. Rev. Rheumatol., 2010, 6:99-105

[2] Holloway KL et al. Non-hip and non-vertebral fractures: the neglected fracture sites. Osteoporos. Int., 2016, 27:905-913

[3] Tran T et al. Population-wide impact of non-hip non-vertebral fractures on mortality. J. Bone Miner. Res., 2017, 32:1802-1810

[4] Mackey DC et al. Effects of antiresorptive treatment on nonvertebral fracture outcomes. J. Bone Miner. Res., 2011, 26:2411-2418

[5] Baron R, Hesse E. Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J. Clin. Endocrinol. Metab., 2012, 97:311-325

[6] Keshawarz NM, Recker RR. Expansion of the medullary cavity at the expense of cortex in postmenopausal osteoporosis. Metab. Bone Dis. & Relat. Res., 1984, 5:223-228

[7] Mazess RB. Fracture risk: a role for compact bone. Calcif. Tissue Int., 1990, 47:191-193

[8] Zebaze RM et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet, 2010, 375:1729-1736

[9] Burr DB. Cortical bone: a target for fracture prevention? Lancet, 2010, 375:1672-1673

[10] Ohlsson C et al. Cortical bone area predicts incident fractures independently of areal bone mineral density in older men. J. Clin. Endocrinol. Metab., 2016, 102:516-524 jc20163177

[11] Reeve J. Role of cortical bone in hip fracture. Bone. Rep., 2017, 6:867

[12] Simsek Kiper PO et al. Cortical-bone fragility--insights from sFRP4 deficiency in Pyle’s disease. N. Engl. J. Med., 2016, 374:2553-2562

[13] Brommage R. Genetic approaches to identifying novel osteoporosis drug targets. J. Cell. Biochem., 2015, 116:2139-2145

[14] Zambrowicz BP, Sands AT. Knockouts model the 100 best-selling drugs--will they model the next 100? Nat. Rev. Drug. Discov., 2003, 2:38-51

[15] Brommage R. High-throughput screening of mouse gene knockouts identifies established and novel skeletal phenotypes. Bone Res., 2014, 2:14034

[16] Plewczynski D, Rychlewski L. Meta-basic estimates the size of druggable human genome. J. Mol. Model., 2009, 15:695-699

[17] Russ AP, Lampel S. The druggable genome: an update. Drug Discov. Today, 2005, 10:1607-1610

[18] Vogel P et al. Amelogenesis imperfecta and other biomineralization defects in Fam20a and Fam20c null mice. Vet. Pathol., 2012, 49:998-1017

[19] Xing W et al. Targeted disruption of leucine-rich repeat kinase 1 but not leucine-rich repeat kinase 2 in mice causes severe osteopetrosis. J. Bone Miner. Res., 2013, 28:1962-1974

[20] Whyte MP et al. Raine syndrome (OMIM #259775), caused by FAM20C mutation, is congenital sclerosing osteomalacia with cerebral calcification (OMIM 259660). J. Bone Miner. Res., 2017, 32:757-769

[21] Iida A et al. Identification of biallelic LRRK1 mutations in osteosclerotic metaphyseal dysplasia and evidence for locus heterogeneity. J. Med. Genet., 2016, 53:568-574

[22] Ashikov, A. et al. Integrating glycomics and genomics uncovers SLC10A7 as essential factor for bone mineralization by regulating post-Golgi protein transport and glycosylation. Hum. Mol. Genet. 27, 3029–3045 (2018).

[23] Zheng HF et al. WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS. Genet., 2012, 8:e1002745

[24] Moverare-Skrtic S et al. Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures. Nat. Med., 2014, 20:1279-1288

[25] Wergedal JE, Kesavan C, Brommage R, Das S, Mohan S. Role of WNT16 in the regulation of periosteal bone formation in female mice. Endocrinology, 2015, 156:1023-1032

[26] Janda CY, Waghray D, Levin AM, Thomas C, Garcia KC. Structural basis of Wnt recognition by Frizzled. Science, 2012, 337:59-64

[27] Kakugawa S et al. Notum deacylates Wnt proteins to suppress signalling activity. Nature, 2015, 519:187-192

[28] Zhang X et al. Notum is required for neural and head induction via Wnt deacylation, oxidation, and inactivation. Dev. Cell., 2015, 32:719-730

[29] Cosman F et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med., 2016, 375:1532-1543

[30] Vogel P et al. Dentin dysplasia in Notum knockout mice. Vet. Pathol., 2016, 53:853-862

[31] Halt K, Vainio S. Coordination of kidney organogenesis by Wnt signaling. Pediatr. Nephrol., 2014, 29:737-744

[32] Boivin FJ, Sarin S, Evans JC, Bridgewater D. The good and bad of β-catenin in kidney development and renal dysplasia. Front. Cell. Dev. Biol., 2015, 3:81

[33] Cooper DN, Krawczak M, Polychronakos C, Tyler-Smith C, Kehrer-Sawatzki H. Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease. Hum. Genet., 2013, 132:1077-1130

[34] Dickinson ME et al. High-throughput discovery of novel developmental phenotypes. Nature, 2016, 537:508-514

[35] Hupkes M, Sotoca AM, Hendriks JM, van Zoelen EJ, Dechering KJ. MicroRNA miR-378 promotes BMP2-induced osteogenic differentiation of mesenchymal progenitor cells. Bmc. Mol. Biol., 2014, 15

[36] Torisu Y et al. Human homolog of NOTUM, overexpressed in hepatocellular carcinoma, is regulated transcriptionally by beta-catenin/TCF. Cancer Sci., 2008, 99:1139-1146

[37] Proffitt KD, Virshup DM. Precise regulation of porcupine activity is required for physiological Wnt signaling. J. Biol. Chem., 2012, 287:34167-34178

[38] Han Q et al. 4H-Thieno[3,2-c]chromene based inhibitors of Notum Pectinacetylesterase. Bioorg. & Med. Chem. Lett., 2016, 26:1184-1187

[39] Tarver JE Jr et al. Stimulation of cortical bone formation with thienopyrimidine based inhibitors of Notum Pectinacetylesterase. Bioorg. & Med. Chem. Lett., 2016, 26:1525-1528

[40] Chen Y, Black DS, Reilly PJ. Carboxylic ester hydrolases: classification and database derived from their primary, secondary, and tertiary structures. Protein Sci., 2016, 25:1942-1953

[41] Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat. Med., 2013, 19:179-192

[42] Lerner UH, Ohlsson C. The WNT system: background and its role in bone. J. Intern. Med., 2015, 277:630-649

[43] Brommage R, Ohlsson C. Translational studies provide insights for the etiology and treatment of cortical bone osteoporosis. Best. Pract. Res. Clin. Endocrinol. Metab., 2018, 32:329-340

[44] Ohlsson C et al. Inducible Wnt16 inactivation: WNT16 regulates cortical bone thickness in adult mice. J. Endocrinol., 2018, 237:113-122

[45] Pead MJ, Skerry TM, Lanyon LE. Direct transformation from quiescence to bone formation in the adult periosteum following a single brief period of bone loading. J. Bone Miner. Res., 1988, 3:647-656

[46] Yao W et al. Anabolic effect of prostaglandin E2 on cortical bone of aged male rats comes mainly from modeling-dependent bone gain. Bone, 1999, 25:697-702

[47] Kim SW et al. Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. J. Bone Miner. Res., 2012, 27:2075-2084

[48] Kim SW et al. Sclerostin antibody administration converts bone lining cells into active osteoblasts. J. Bone Miner. Res., 2016, 32:892-901

[49] Langdahl B, Ferrari S, Dempster DW. Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. Ther. Adv. Musculoskelet. Dis., 2016, 8:225-235

[50] Zhang X et al. Characterization of Tiki, a new family of Wnt-specific metalloproteases. J. Biol. Chem., 2016, 291:2435-2443

[51] Khosla S. Bone diseases: Romosozumab - on track or derailed? Nat. Rev. Endocrinol., 2017, 13:697-698

[52] Brommage R, Vafai H. Rapid embedding protocol for visualizing bone mineral and matrix. Calcif. Tissue Int., 2000, 67:479

[53] Binkley N et al. Bone loss detection in rats using a mouse densitometer. J. Bone Miner. Res., 2003, 18:370-375

[54] Brommage R, Jeter-Jones S, Xiong W, Champ R, Liu J. Mouse femoral neck architecture determined by microCT reflects skeletal architecture observed at other bone sites. J. Bone Miner. Res., 2013, 28 Suppl 1 S347-S348

[55] Granholm S, Henning P, Lindholm C, Lerner UH. Osteoclast progenitor cells present in significant amounts in mouse calvarial osteoblast isolations and osteoclastogenesis increased by BMP-2. Bone, 2013, 52:83-92

[56] Petryszak R et al. Expression Atlas update--an integrated database of gene and protein expression in humans, animals and plants. Nucleic Acids Res., 2016, 44:D746-D752

Funding

The work in Gothenburg was supported by the Swedish Research Council and by grants from the Swedish Government (under the Avtal om Läkarutbildning och Medicinsk Forskning [Agreement for Medical Education and Research]), the Lundberg Foundation, the Torsten Söderberg Foundation, the Novo Nordisk Foundation, the Swedish Foundation for Strategic Research and the Knut and Alice Wallenberg Foundation.